Anti-NME antibody and method of treating cancer or cancer metastasis

Abstract

The present application discloses anti-NMR antibodies and their use in treating or preventing diseases.

The invention claimed is: 
     
       1. A nucleic acid encoding a monoclonal antibody, a bispecific antibody, a bispecific T-cell engager, a Fab, or a single chain variable fragment antibody (scFv) comprising:
 (a) a heavy chain variable region (HCV) comprising the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and
 a light chain variable region (LCV) comprising complementarity determining regions (CDRs) comprising a light chain CDR1 (LC-CDR1) comprising the sequence of SEQ ID NO: 434, an LC-CDR2 comprising the sequence of SEQ ID NO: 435, and an LC-CDR3 comprising the sequence of SEQ ID NO: 436; or 
 
 (b) an HCV comprising CDRs comprising a heavy chain CDR1 (HC-CDR1) comprising the sequence of SEQ ID NO: 429, an HC-CDR2 comprising the sequence of SEQ ID NO: 430, and an HC-CDR3 comprising the sequence of SEQ ID NO: 431; and
 an LCV comprising the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185; 
 
 wherein the monoclonal antibody, the bispecific antibody, the bispecific T-cell engager, the Fab, or the scFv binds to NME7. 
 
     
     
       2. The nucleic acid of  claim 1 , wherein the HCV comprises the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and the LCV comprises the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185. 
     
     
       3. The nucleic acid of  claim 1 , wherein the HCV comprises the sequence of SEQ ID NO: 1164, and the LCV comprises the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185. 
     
     
       4. The nucleic acid of  claim 1 , wherein the HCV comprises the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and the LCV comprises the sequence of SEQ ID NO: 1185. 
     
     
       5. The nucleic acid of  claim 1 , wherein the nucleic acid encodes the monoclonal antibody. 
     
     
       6. The nucleic acid of  claim 1 , wherein the nucleic acid encodes the bispecific antibody. 
     
     
       7. The nucleic acid of  claim 1 , wherein the nucleic acid encodes the bispecific T-cell engager. 
     
     
       8. The nucleic acid of  claim 1 , wherein the nucleic acid encodes the scFv. 
     
     
       9. A cell comprising the nucleic acid of  claim 1 .